RU2015157407A - A method for the treatment of patients with local prostate cancer belonging to a high risk group of disease progression - Google Patents

A method for the treatment of patients with local prostate cancer belonging to a high risk group of disease progression Download PDF

Info

Publication number
RU2015157407A
RU2015157407A RU2015157407A RU2015157407A RU2015157407A RU 2015157407 A RU2015157407 A RU 2015157407A RU 2015157407 A RU2015157407 A RU 2015157407A RU 2015157407 A RU2015157407 A RU 2015157407A RU 2015157407 A RU2015157407 A RU 2015157407A
Authority
RU
Russia
Prior art keywords
treatment
patients
high risk
disease progression
prostate cancer
Prior art date
Application number
RU2015157407A
Other languages
Russian (ru)
Other versions
RU2625598C2 (en
Inventor
Александр Владимирович Фаенсон
Алексей Николаевич Шевченко
Дмитрий Александрович Швырёв
Михаил Владимирович Тараканов
Максим Николаевич Дурицкий
Original Assignee
Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации filed Critical Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации
Priority to RU2015157407A priority Critical patent/RU2625598C2/en
Publication of RU2015157407A publication Critical patent/RU2015157407A/en
Application granted granted Critical
Publication of RU2625598C2 publication Critical patent/RU2625598C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (1)

Способ лечения больных локальным раком простаты, относящихся к группе высокого риска прогрессирования заболевания, включающий интра- и парапростатическое введение химиопрепарата - радиомодификатора 5-фторурацила на фоне проведения брахитерапии и дистанционной лучевой терапии, отличающийся тем, что за сутки до проведения брахитерапии выполняется однократное интрапростатическое введение 500 мг 5-фторурацила, разведенного 20 мл натрия хлорида 0,9%, в визуализируемые при трансректальном ультразвуковом исследовании гипоэхогенные участки ткани простаты; затем, в день начала проведения второго этапа лечения и в середине его проведения выполняется введение 500 мг 5-фторурацила, разведенного 20 мл натрия хлорида 0,9% в визуализируемые при трансректальном ультразвуковом исследовании гипоэхогенные участки ткани простаты и в парапростатическое пространство справа и слева.A method for the treatment of patients with local prostate cancer, which are at high risk of disease progression, including intra- and para-prostatic administration of a chemotherapeutic drug - 5-fluorouracil radio modifier against the background of brachytherapy and remote radiation therapy, characterized in that a single intra-prostatic administration is performed a day before brachytherapy 500 mg of 5-fluorouracil, diluted with 20 ml of sodium chloride 0.9%, in the hypoechoic areas of the tissue visualized by transrectal ultrasound ani prostate; then, on the day the second stage of treatment is started and in the middle of it, 500 mg of 5-fluorouracil diluted with 20 ml of 0.9% sodium chloride is introduced into the hypoechoic portions of the prostate tissue visualized during transrectal ultrasound examination and into the para-prostatic space on the right and left.
RU2015157407A 2015-12-31 2015-12-31 Method for treatment of patients with local prostate cancer, belonging to group of high risk of disease progression RU2625598C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015157407A RU2625598C2 (en) 2015-12-31 2015-12-31 Method for treatment of patients with local prostate cancer, belonging to group of high risk of disease progression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015157407A RU2625598C2 (en) 2015-12-31 2015-12-31 Method for treatment of patients with local prostate cancer, belonging to group of high risk of disease progression

Publications (2)

Publication Number Publication Date
RU2015157407A true RU2015157407A (en) 2017-07-05
RU2625598C2 RU2625598C2 (en) 2017-07-17

Family

ID=59309248

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015157407A RU2625598C2 (en) 2015-12-31 2015-12-31 Method for treatment of patients with local prostate cancer, belonging to group of high risk of disease progression

Country Status (1)

Country Link
RU (1) RU2625598C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694373C2 (en) * 2017-10-16 2019-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method of castration-resistant prostate cancer treatment
RU2675695C1 (en) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Method of treating the prostatic gland cancer of a high and a very high risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098443A2 (en) * 2006-02-17 2007-08-30 Waseet Vance Apparatuses and techniques for bioactive drug delivery in the prostate gland
HUE034465T2 (en) * 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
RU2454256C1 (en) * 2011-04-27 2012-06-27 ФГУ "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации Method of treating cervical cancer

Also Published As

Publication number Publication date
RU2625598C2 (en) 2017-07-17

Similar Documents

Publication Publication Date Title
RU2017126610A (en) THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNC MOLECULES AIMED AGAINST HSP47
RU2016102158A (en) APPLICATION OF ERIBULIN AND LENVATINIB AS A COMBINED THERAPY FOR TREATMENT OF CANCER
Al-Mamgani et al. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis
CN104039952A (en) Small molecule enhancer for dendritic cell cancer vaccines
RU2015157407A (en) A method for the treatment of patients with local prostate cancer belonging to a high risk group of disease progression
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
Jonska-Gmyrek et al. Radiotherapy in testicular germ cell tumours–a literature review
RU2018114457A (en) TREATMENT OF SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER
RU2400267C1 (en) Method of optimising treatment of locally advanced and inoperable cancer of esophagus
Fartushnaya et al. Reducing the risk of recurrent ischemic stroke after transient ischemic attack along with neuroprotective and antiaggregant therapy
RU2682293C2 (en) Method for treating lung cancer
MX2021015467A (en) Compounds and methods of use.
BR112022001814A2 (en) Multifocal cancer treatment methods
RU2429032C1 (en) Method of treating oropharyngeal squamous cell carcinoma
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
RU2666694C1 (en) Method for treating low-lying tumors of rectum and anal canal
RU2691345C1 (en) Method of treating rectal cancer
Xu et al. Palliative local radiotherapy in the treatment of tumor-stage cutaneous T-cell lymphoma/mycosis fungoides
Abou Elkasem et al. TOP2A and HER2neu Evaluation in Malignant Pleural Mesothelioma
RU2014120624A (en) METHOD FOR TREATING A STROKE
Cha et al. EP-1292: Stereotactic body radiotherapy for liver metastases in patients with oligorecurrence from variable tumor
RU2016143220A (en) ANTI-TUMOR AGENT CONTAINING AN ANTUMOR PLATINUM COMPLEX, AND ANTITUM AN EFFECT AMPLIFIER
Medina et al. Clinical cases MIR: Long survivors in oncology
Borzenko et al. Effectiveness of photodynamic therapy of a patient with early central lung cancer and cystic fibrosis
Dalsania et al. 1155 The Use of Cryoablation for the Treatment of Gastric Cancer

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180101